Compare D Wave Quantum Inc (QBTS) vs TransMedics Group Inc (TMDX) Price & Performance

QBTS trades at $17.67, down 33% year-to-date, with a bearish technical signal and negative profitability metrics including a net income margin of -2,001.59% for 2026. Recent news highlights a $100 million U.S. government funding injection via the CHIPS Act, boosting sentiment amid ongoing losses and legal investigations.

The stock faces high risk from persistent losses and lofty valuations but holds long-term potential in quantum computing, supported by unanimous analyst buy ratings and a $37.00 consensus price target. Investors must weigh government backing against cash burn and competitive pressures in a nascent industry.

TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.

The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.